ProQR Therapeutics/$PRQR

1D1W1MYTD1Y5YMAX

About ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
Ticker
$PRQR
Sector
Health
Primary listing
NASDAQ
Employees
187

PRQR Metrics

BasicAdvanced
$262M
-
-$0.46
0.06
-

What the Analysts think about PRQR

Analyst ratings (Buy, Hold, Sell) for ProQR Therapeutics stock.
Analyst projections of the future price of ProQR Therapeutics stock.

PRQR Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

PRQR Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing PRQR

Funds
Fund name
Fund size
$PRQR weighting
Xtrackers S&P 500 Swap£XSPX
£3.1B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.